Long Term Outcomes of Vivity Intra Ocular Lens(IOL) Versus Control (REVIVE)

John Berdahl, MD

Status: Completed

Conditions: Cataract

Treatments: Device: ACRYSOF IQ IOL Control Group; Device: Vivity ACRYSOF IQ IOL Group

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT04561570

The REVIVE Study

Details and patient eligibility

About

Evaluate the long-term (>1 yr) outcomes of the Vivity IOL. The investigator will use similar measurements and procedures to the ones performed on these subjects during the FDA clinical trial.

Enrollment: 32 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Must have participated in the FDA study at one of the included sites

Exclusion criteria

None

Trial design

32 participants in 2 patient groups

Study Group: Vivity ACRYSOF IQ IOL

Description:

Subjects that were implanted with the Vivity ACRYSOF IQ extended depth of focus IntaOcular Lens

Treatment:

Device: Vivity ACRYSOF IQ IOL Group

Control Group: ACRYSOF IQ IOL

Description:

Control Group: Subject that were implanted with the ACRYSOF IQ Monofocal IntaOcular Lens

Treatment:

Device: ACRYSOF IQ IOL Control Group